Select Publications
Conference Abstracts
, 2019, 'Abstract 4741: Re-evaluating the role of P-glycoprotein in the resistance of high-risk neuroblastoma to standard-of-care chemotherapies', in Cancer Research, American Association for Cancer Research (AACR), Vol. 79, pp. 4741 - 4741, http://dx.doi.org/10.1158/1538-7445.am2019-4741
, 2019, 'RESULTS OF THE ZERO CHILDHOOD CANCER INTEGRA-TM PRECISION MEDICINE PLATFORM FOR PAEDIATRIC HIGH-RISK BRAIN TUMOURS', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, CA, San Francisco, Vol. 21, pp. 118 - 118, presented at 5th Biennial Conference of the Society-for-Neuro-Oncology on Pediatric Neuro-Oncology Basic and Translational Research, CA, San Francisco, 03 May 2019 - 04 May 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000473243700229&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2019, 'Alyref is a novel binding partner and co-factor for MYCN-driven oncogenesis in neuroblastoma', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, GA, Atlanta, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), GA, Atlanta, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.AM2019-3659
, 2019, 'Establishment of patient-derived xenograft models for high-risk neuroblastoma', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, GA, Atlanta, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), GA, Atlanta, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.AM2019-2884
, 2019, 'Re-evaluating the role of P-glycoprotein in the resistance of high-risk neuroblastoma to standard-of-care chemotherapies', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, GA, Atlanta, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), GA, Atlanta, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.SABCS18-4741
, 2019, 'Zero Childhood Cancer: A comprehensive precision medicine platform for children with high-risk cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Atlanta, GA, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), Atlanta, GA, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.AM2019-3111
, 2018, 'Zero Childhood Cancer: A Comprehensive Precision Medicine Platform for Children with High-Risk Cancer', in PEDIATRIC BLOOD & CANCER, WILEY, Vol. 65, pp. S643 - S644, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000445195005221&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2018, 'TARGETING THE POLYAMINE PATHWAY AS A NOVEL THERAPEUTIC TREATMENT AGAINST DIFFUSE INTRINSIC PONTINE GLIOMA', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, CO, Denver, Vol. 20, pp. 49 - 49, presented at 18th International Symposium on Pediatric Neuro-Oncology (ISPNO), CO, Denver, 30 June 2018 - 03 July 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000438339000097&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2018, 'DIPG-01. TARGETING THE POLYAMINE PATHWAY AS A NOVEL THERAPEUTIC TREATMENT AGAINST DIFFUSE INTRINSIC PONTINE GLIOMA', in Neuro-Oncology, Oxford University Press (OUP), Vol. 20, pp. i49 - i49, http://dx.doi.org/10.1093/neuonc/noy059.095
, 2018, 'Integrated genomics: drug screening and personalized xenograft development approach to identify precision treatments for aggressive pediatric brain tumors', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, IL, Chicago, Vol. 78, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), IL, Chicago, 14 April 2018 - 18 April 2018, http://dx.doi.org/10.1158/1538-7445.AM2018-LB-137
, 2018, 'Zero Childhood Cancer: A comprehensive precision medicine platform for children with high-risk cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, IL, Chicago, Vol. 78, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), IL, Chicago, 14 April 2018 - 18 April 2018, http://dx.doi.org/10.1158/1538-7445.AM2018-LB-138
, 2018, 'PO-028 Effective targeting of NAD+biosynthesis in patient-derived xenograft models of high-risk paediatric acute lymphoblastic leukaemia', in ESMO Open, Elsevier BV, Vol. 3, pp. A238 - A238, http://dx.doi.org/10.1136/esmoopen-2018-eacr25.563
, 2017, 'REPOSITIONING EXISTING DRUGS AS NOVEL THERAPEUTICS: OXIDATIVE STRESS AS A TARGET FOR HIGH-RISK LEUKAEMIA IN CHILDREN', in HAEMATOLOGICA, FERRATA STORTI FOUNDATION, SPAIN, Madrid, Vol. 102, pp. 27 - 27, presented at 22nd Congress of the European-Hematology-Association, SPAIN, Madrid, 22 June 2017 - 25 June 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000404127001055&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2017, 'Pilot study of a comprehensive precision medicine platform for children with high-risk cancer.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 35, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2017 - 06 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.10539
, 2017, 'TRTH-05. PREDICTORS OF SUCCESS OF PHASE 2 PAEDIATRIC ONCOLOGY CLINICAL TRIALS', in Neuro-Oncology, Oxford University Press (OUP), Vol. 19, pp. iv52 - iv52, http://dx.doi.org/10.1093/neuonc/nox083.217
, 2016, 'Comparison of MRD Levels and Gene Expression Patterns in MLL-R Versus Non-MLL Infant ALL', in BLOOD, AMER SOC HEMATOLOGY, CA, San Diego, Vol. 128, presented at 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), CA, San Diego, 03 December 2016 - 06 December 2016, http://dx.doi.org/10.1182/blood.V128.22.1740.1740
, 2015, 'Improved Concordance of Minimal Residual Disease Measurements By Quantitative PCR and 10-Color Flow Cytometry in Pediatric Acute Lymphoblastic Leukemia', in BLOOD, AMER SOC HEMATOLOGY, FL, Orlando, Vol. 126, presented at 57th Annual Meeting of the American-Society-of-Hematology, FL, Orlando, 05 December 2015 - 08 December 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000368020102126&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2015, 'Selective and rapid killing of mixed lineage leukemia and CALM-AF10 leukemia by SM7, a novel small molecule identified by chemical library screening', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, FL, Fort Lauderdale, Vol. 76, presented at AACR Special Conference on Advances in Pediatric Cancer Research - From Mechanisms and Models to Treatment and Survivorship, FL, Fort Lauderdale, 09 November 2015 - 12 November 2015, http://dx.doi.org/10.1158/1538-7445.PEDCA15-B23
, 2015, 'The FACT histone chaperone complex is highly expressed in aggressive drug refractory childhood cancers and the anti-FACT compound CBL0137 represents a highly promising therapeutic approach in this setting', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, PA, Philadelphia, Vol. 75, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.AM2015-1611
, 2015, 'The long noncoding RNA MALAT1 promotes hypoxia-driven angiogenesis by upregulating pro-angiogenic gene expression in neuroblastoma cells', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, PA, Philadelphia, Vol. 75, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.AM2015-146
, 2011, 'THE VALUE OF MONITORING FOR MRD AT LATE TIMEPOINTS IN PAEDIATRIC ALL TREATMENT', in PEDIATRIC BLOOD & CANCER, WILEY PERIODICALS, INC, Vol. 57, pp. 707 - 707, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000295239600003&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2011, 'Development of organ-selective neuroblastoma cell lines to identify genes mediating bone marrow and liver colonization', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Vol. 71, http://dx.doi.org/10.1158/1538-7445.AM2011-5237
, 2011, 'SIRT1 promotes N-Myc oncogenesis stabilizing N-Myc protein', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Vol. 71, http://dx.doi.org/10.1158/1538-7445.AM2011-3027
, 2008, 'The value of monitoring for minimal residual disease post-transplant in children with acute lymphoblastic leukaemia', in British Journal of Haematology, Blackwell Publishing Ltd, Oxford, England, pp. 102 - 102, presented at Abstracts of the British Society of Haematology 48th Annual Scientific Meeting, incorporating the 6th Bi-Annual I-BFM Leukaemia Symposium
, 2006, 'Relapse in children with acute lymphoblastic leukaemia is associated with selection of a pre-existing drug resistance subclone', in EJC SUPPLEMENTS, PERGAMON-ELSEVIER SCIENCE LTD, Vol. 4, pp. 81 - 81, http://dx.doi.org/10.1016/S1359-6349(06)70257-9
, 2006, 'Sensitisation of neuroblastorna tumours to chemotherapy by use of a novel class of MRP1 small molecule inhibitor', in EJC SUPPLEMENTS, PERGAMON-ELSEVIER SCIENCE LTD, Vol. 4, pp. 54 - 54, http://dx.doi.org/10.1016/S1359-6349(06)70175-6
, 2004, 'Minimal residual disease in childhood acute lymphoblastic leukemia: A comparative study of flow cytometry and quantitative real-time polymerase chain reaction (RQ-PCR)', in BLOOD, AMER SOC HEMATOLOGY, CA, San Diego, Vol. 104, pp. 209B - 209B, presented at 46th Annual Meeting of the American-Society-of-Hematology, CA, San Diego, 04 December 2004 - 07 December 2004, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000225127700834&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2004, 'Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia: A Comparative Study of Flow Cytometry and Quantitative Real-Time Polymerase Chain Reaction (RQ-PCR).', in Blood, American Society of Hematology, Vol. 104, pp. 4504 - 4504, http://dx.doi.org/10.1182/blood.v104.11.4504.4504
Preprints
, 2025, Inclusion of JNK-independent drugs within multi-agent chemotherapy improves response in relapsed high-risk neuroblastoma, http://dx.doi.org/10.1101/2025.04.26.650760
, 2024, The polyamine transporter ATP13A3 mediates DFMO-induced polyamine uptake in neuroblastoma, http://dx.doi.org/10.1101/2024.02.20.581161
Other
, 2023, Data from Targeting TSLP-Induced Tyrosine Kinase Signaling Pathways in <i>CRLF2</i>-Rearranged Ph-like ALL, http://dx.doi.org/10.1158/1541-7786.c.6540834.v1
, 2023, Data from Targeting TSLP-Induced Tyrosine Kinase Signaling Pathways in <i>CRLF2</i>-Rearranged Ph-like ALL, http://dx.doi.org/10.1158/1541-7786.c.6540834
, 2023, Supplementary Figures 1-7 from Targeting TSLP-Induced Tyrosine Kinase Signaling Pathways in <i>CRLF2</i>-Rearranged Ph-like ALL, http://dx.doi.org/10.1158/1541-7786.22514508.v1
, 2023, Supplementary Figures 1-7 from Targeting TSLP-Induced Tyrosine Kinase Signaling Pathways in <i>CRLF2</i>-Rearranged Ph-like ALL, http://dx.doi.org/10.1158/1541-7786.22514508
, 2023, Supplementary Tables 1-8 from Targeting TSLP-Induced Tyrosine Kinase Signaling Pathways in <i>CRLF2</i>-Rearranged Ph-like ALL, http://dx.doi.org/10.1158/1541-7786.22514505.v1
, 2023, Supplementary Tables 1-8 from Targeting TSLP-Induced Tyrosine Kinase Signaling Pathways in <i>CRLF2</i>-Rearranged Ph-like ALL, http://dx.doi.org/10.1158/1541-7786.22514505
, 2023, Data from Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma, http://dx.doi.org/10.1158/1078-0432.c.6530664.v1
, 2023, Data from Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma, http://dx.doi.org/10.1158/1078-0432.c.6530664
, 2023, Data from Suppression of ABCE1-Mediated mRNA Translation Limits N-MYC–Driven Cancer Progression, http://dx.doi.org/10.1158/0008-5472.c.6511953.v1
, 2023, Data from Suppression of ABCE1-Mediated mRNA Translation Limits N-MYC–Driven Cancer Progression, http://dx.doi.org/10.1158/0008-5472.c.6511953
, 2023, Data from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy, http://dx.doi.org/10.1158/1078-0432.c.6530307.v1
, 2023, Data from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy, http://dx.doi.org/10.1158/1078-0432.c.6530307
, 2023, Supplementary Figure Legends from Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma, http://dx.doi.org/10.1158/1078-0432.22481343.v1
, 2023, Supplementary Figure Legends from Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma, http://dx.doi.org/10.1158/1078-0432.22481343
, 2023, Supplementary Figure S1 from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy, http://dx.doi.org/10.1158/1078-0432.22479852
, 2023, Supplementary Figure S1 from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy, http://dx.doi.org/10.1158/1078-0432.22479852.v1
, 2023, Supplementary Figure S2 from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy, http://dx.doi.org/10.1158/1078-0432.22479849.v1
, 2023, Supplementary Figure S2 from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy, http://dx.doi.org/10.1158/1078-0432.22479849
, 2023, Supplementary Figure S3 from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy, http://dx.doi.org/10.1158/1078-0432.22479846.v1
, 2023, Supplementary Figure S3 from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy, http://dx.doi.org/10.1158/1078-0432.22479846